Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL vs MICRAININ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Sedative,Hypnotic for short-term treatment of insomnia,Preoperative sedation
Tension headache,Migraine (off-label),Muscle contraction headache
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
Terminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Hepatic metabolism via cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4); undergoes hydroxylation and glucuronidation; active metabolites include hydroxybutabarbital.
Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes.
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Approximately 20-25% bound to plasma proteins, predominantly albumin.
70-80% bound to albumin
Approximately 1.0 L/kg, indicating distribution throughout total body water and extensive tissue binding.
0.3-0.5 L/kg; indicates moderate distribution into total body water
Oral bioavailability is nearly 100% (50-70% reported in some texts, but butabarbital is completely absorbed; first-pass metabolism is minimal).
Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100%
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%.
Not studied; use caution with Cr Cl <30 m L/min. Avoid if severe renal impairment (Cr Cl <15 m L/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor.
Children 2-6 years: 25-50 mg orally 3-4 times daily; children 6-12 years: 50-100 mg orally 3-4 times daily; maximum 200 mg/day.
Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred.
Initiate at 25-50 mg orally 3 times daily; increase cautiously to avoid excessive sedation and falls, maximum 200 mg/day.
Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function.
Butabarbital has no FDA boxed warning.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Risk of dependence, tolerance, and withdrawal symptoms upon discontinuation; respiratory depression, especially with high doses or in patients with respiratory compromise; CNS depression may impair ability to drive or operate machinery; concomitant use with other CNS depressants (e.g., alcohol, opioids) increases risk of profound sedation and respiratory depression; geriatric patients may be more sensitive to effects; use with caution in patients with hepatic or renal impairment.
Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease.
Hypersensitivity to barbiturates; porphyria (can exacerbate); severe respiratory insufficiency; history of addiction to sedative-hypnotics; acute or chronic pain (may cause paradoxical excitement); pregnancy (especially third trimester) and lactation.
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
Grapefruit juice may decrease metabolism of butabarbital; avoid concurrent consumption. Alcohol increases CNS depression and should be avoided. No specific food restrictions otherwise.
Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity.
First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fetal dependence and withdrawal syndrome; neonatal respiratory depression if used near term; increased risk of neurobehavioral effects. Barbiturates cross the placenta rapidly.
MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage.
Butabarbital is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.4–0.6. With therapeutic doses, infant serum levels are usually low; however, chronic high maternal doses may cause sedation or withdrawal in the nursing infant. Caution is recommended; alternate agents may be preferred if infant sedation occurs.
Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital.
Pregnancy can alter butabarbital pharmacokinetics due to increased hepatic metabolism and volume of distribution. Serum concentrations may decrease; therapeutic drug monitoring is recommended if used chronically. Dose adjustments may be necessary to maintain efficacy, but due to risks, use is generally avoided. If used, start with lowest effective dose and monitor for clinical response and toxicity.
No specific pharmacokinetic data for MICRAININ during pregnancy. Pregnancy can alter metabolism of acetaminophen and caffeine. Butalbital clearance may increase due to enhanced hepatic metabolism. However, dose adjustments are not typically recommended. Use the lowest effective dose for the shortest duration.
Butabarbital is a short-acting barbiturate with rapid onset. It is primarily used for sedation and insomnia but has high abuse potential. Avoid use in patients with porphyria, severe hepatic impairment, or respiratory insufficiency. Abrupt discontinuation after prolonged use may precipitate withdrawal including seizures. Barbiturates induce CYP3A4 and other hepatic enzymes, reducing efficacy of oral contraceptives, warfarin, and corticosteroids. Use with caution in elderly due to increased risk of falls and cognitive impairment.
MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as withdrawal reactions such as anxiety, tremors, or seizures can occur.,May cause drowsiness or dizziness; do not drive or operate machinery until you know how this medicine affects you.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) as they increase risk of severe sedation and respiratory depression.,Use effective contraception while taking this medication as it may reduce hormonal contraceptive effectiveness.,Store in a secure place away from children and others, as it can cause dependence and is habit-forming.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol while taking this medication.,Do not exceed 4000 mg acetaminophen per day from all sources.,This medication can be habit-forming; do not share with others.,May cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain.,Do not use for more than 5 days per week to avoid rebound headaches.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL vs MICRAININ, answered by our medical review team.
BUTABARBITAL is a Barbiturate that works by Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.. MICRAININ is a Barbiturate Combination Analgesic that works by MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL and MICRAININ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL is: 50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.. The standard adult dose of MICRAININ is: 2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTABARBITAL and MICRAININ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTABARBITAL is classified as Category C. First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fe. MICRAININ is classified as Category C. MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, par. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.